20th Mar 2015 09:00
Skyepharma wins "Best Performing Share" and "Turnaround of the Year" awards at the annual PLC Awards
LONDON, ENGLAND, 20 March 2015 - Skyepharma PLC (LSE: SKP), the expert oral and inhalation drug development company, today announces that it has been awarded the "Best Performing Share" and "Turnaround of the Year" awards at the 2014 PLC Awards.
Peter Grant, Chief Executive Officer of Skyepharma, commented:
"2014 was a year of transformation and growth for Skyepharma and we are honoured to be recognised by these awards which reflect the great progress made by the Group. The capital raise, repayment of the bond debt and rejuvenated product portfolio demonstrate the success achieved in 2014. I would like to thank all employees for their outstanding contribution and hard work, and our shareholders for their on-going support and confidence in the management team's strategy."
The "Best Performing Share" award is for Main Market listed companies outside the FTSE 100 and is based on published data from 1 January to 31 December 2014. The "Turnaround of the Year" award is based on companies that have completed the most innovative turnaround of the year in a way likely to save or substantially improve the business. Further, the award required that the winner be a business that is now strongly positioned for future growth, rather than a business that had simply staved off the inevitable or one that was effectively being run solely to service its existing debt burden.
The PLC Awards has been running for 29 years and recognises success and achievement amongst small and medium-sized publicly quoted companies in the UK.
- Ends -
For further information please contact:
Skyepharma PLC | |
Peter Grant, Chief Executive Officer Andrew Derodra, Chief Financial Officer | +44 (0)20 7881 0524 |
Jonathan Birt, Investor and Media Relations
| +44 (0)7860 361746 |
N+1 Singer | |
Shaun Dobson/Jen Boorer | +44 (0)20 7496 3000 |
FTI Consulting | |
Julia Phillips/Rob Winder/Natalie Garland-Collins | +44 (0)20 3727 1000 |
About Skyepharma PLC
Skyepharma combines proven scientific expertise with validated proprietary technologies to develop innovative oral and inhalation pharmaceutical products. The Group's licenses cover 16 approved inhalation, oral, topical and injectable products, which generate milestones, recurring royalties, and in some cases, product supply revenues. The Group also earns milestones and contract development revenues from new product developments. Products developed by Skyepharma are marketed by some of the world's most respected pharmaceutical companies. For more information, visit www.skyepharma.com
Related Shares:
SKP.L